Dr Kaufman speaks with ecancertv at ASCO 2016 to discuss the results of phase II JAVELIN Merkel 200 trial, in which patients with metastatic Merkl cell carcinoma received avelumab, a PD-L1 checkpoint inhibitor.
Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with Merkel cell polyomavirus, with limited therapeutic options after 1st-line chemotherapy.
Dr Kaufman describes the results of the JAVELIN trial in which, of a cohort of 88, six patients (9.8%) achieved complete responses, 12 (19.7%) had partial responses, and 7 (11.5%) had stable disease (83.3% responses were ongoing).
He also details the ongoing progression free survival data, and offers that additional clinical evaluation of avelumab for is warranted.
Learn more about radiation therapy treatment from a patient's perspective. Find out how long appointments last, what to expect during the treatment, and also what the side effects may be from treatment.
http://www.independent-media.com. Why do some people get cancer, and other people don't? Can this cancer-fighting capability be transferred from one person to another? This fundraising video for a cancer treatment research group seeks funding for a human clinical trial for a game-changing new treatment.
This is my personal experience on my ongoing struggle with the type of cancer known as Non-Hodgkin Lymphoma. Therapeutic grade Sacred Frankincense Essential Oil from www.youngliving.org helped me clear the swelling in a cancerous lymph node on my neck. You can write to me at email@example.com